Cheng, Peter T. W. team published research on Journal of Medicinal Chemistry in 2021 | 105-34-0

Synthetic Route of 105-34-0, Methyl cyanoacetate is an alkyl cyanoacetate ester.
Methyl cyanoacetate is the intermediate product in pharmaceutical organic synthesis as well as in the synthesis of some biologically active compounds used in agriculture. It undergoes calcite or fluorite catalyzed Knövenagel condensation with aromatic aldehydes, giving the corresponding arylidenemalononitriles and (E)-α -cyanocinnamic esters.
Methyl Cyanoacetate is often used as a nucleophile in the electrochemical oxidation of catechols. Methyl Cyanoacetate is also a reagent in the synthesis of Methyl 2-Amino-4-trifluoromethylthiophene-3-carboxylate (M287290); a compound used in the synthesis of DPP-IV inhibitors for treating type 2 diabetes., 105-34-0.

Industrially, the main methods for producing nitriles are ammoxidation and hydrocyanation. 105-34-0, formula is C4H5NO2, Name is Methyl 2-cyanoacetate. Both routes are green in the sense that they do not generate stoichiometric amounts of salts. Synthetic Route of 105-34-0.

Cheng, Peter T. W.;Kaltenbach, Robert F.;Zhang, Hao;Shi, Jun;Tao, Shiwei;Li, Jun;Kennedy, Lawrence J.;Walker, Steven J.;Shi, Yan;Wang, Ying;Dhanusu, Suresh;Reddigunta, Ramesh;Kumaravel, Selvakumar;Jusuf, Sutjano;Smith, Daniel;Krishnananthan, Subramaniam;Li, Jianqing;Wang, Tao;Heiry, Rebekah;Sum, Chi Shing;Kalinowski, Stephen S.;Hung, Chen-Pin;Chu, Ching-Hsuen;Azzara, Anthony V.;Ziegler, Milinda;Burns, Lisa;Zinker, Bradley A.;Boehm, Stephanie;Taylor, Joseph;Sapuppo, Julia;Mosure, Kathy;Everlof, Gerry;Guarino, Victor;Zhang, Lisa;Yang, Yanou;Ruan, Qian;Xu, Carrie;Apedo, Atsu;Traeger, Sarah C.;Cvijic, Mary Ellen;Lentz, Kimberley A.;Tirucherai, Giridhar;Sivaraman, Lakshmi;Robl, Jeffrey;Ellsworth, Bruce A.;Rosen, Glenn;Gordon, David A.;Soars, Matthew G.;Gill, Michael;Murphy, Brian J. research published 《 Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases》, the research content is summarized as follows. The oxycyclohexyl acid BMS-986278 (33) is a potent lysophosphatidic acid receptor 1 (LPA1) antagonist, with a human LPA1Kb of 6.9 nM. The structure-activity relationship (SAR) studies starting from the LPA1 antagonist clin. compound BMS-986020 (1), which culminated in the discovery of 33, are discussed. The detailed in vitro and in vivo preclin. pharmacol. profiles of 33, as well as its pharmacokinetics/metabolism profile, are described. On the basis of its in vivo efficacy in rodent chronic lung fibrosis models and excellent overall ADME (absorption, distribution, metabolism, excretion) properties in multiple preclin. species, 33 was advanced into clin. trials, including an ongoing Phase 2 clin. trial in patients with lung fibrosis (NCT04308681).

Synthetic Route of 105-34-0, Methyl cyanoacetate is an alkyl cyanoacetate ester.
Methyl cyanoacetate is the intermediate product in pharmaceutical organic synthesis as well as in the synthesis of some biologically active compounds used in agriculture. It undergoes calcite or fluorite catalyzed Knövenagel condensation with aromatic aldehydes, giving the corresponding arylidenemalononitriles and (E)-α -cyanocinnamic esters.
Methyl Cyanoacetate is often used as a nucleophile in the electrochemical oxidation of catechols. Methyl Cyanoacetate is also a reagent in the synthesis of Methyl 2-Amino-4-trifluoromethylthiophene-3-carboxylate (M287290); a compound used in the synthesis of DPP-IV inhibitors for treating type 2 diabetes., 105-34-0.

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts